Compare FMC Corp (FMC) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

FMC trades at $8.92, down 1.87% today, reflecting bearish technical signals and weak profitability. The stock shows negative net income margins and ROE, though recent quarterly EPS beat estimates. Cash flow trends are volatile, with 2025 showing negative operational cash flow but positive net cash flow from financing. Analyst consensus is mixed with a near-even split between Buy and Hold ratings, and a price target of $14.60 suggests potential upside. Recent news includes regulatory filings in Brazil and a minority equity investment.

Outlook: FMC faces significant headwinds from declining revenue and negative profitability, but aggressive deleveraging efforts and new product filings offer recovery potential. Risks include high debt, cyclical industry pressures, and execution challenges. The stock may appeal to value investors given low P/S and P/B ratios, but sustained earnings improvement is critical for long-term upside.

INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.

Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.